Dentists in Delavan, WI Accepting Medicare
10 Dentists found. Showing 1 - 10
 Dr. Michael J. Sherman, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1221 Phoenix St, Delavan, WI 53115 Phone: 262-728-6437 |
 Dr. Samantha Ryan Johnson, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 1624 Hobbs Dr Ste 2, Delavan, WI 53115 Phone: 262-740-1010 |
Dr. Benjamin S Johnson, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 134 S 4th St, Delavan, WI 53115 Phone: 262-728-9330 Fax: 262-728-0172 |
Emily Scheff Taibl Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 1624 Hobbs Dr, Suite 2, Delavan, WI 53115 Phone: 262-740-1010 |
Dr. John P Howland, DDS MS PC Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 1421a Racine St, Delavan, WI 53115 Phone: 262-728-1588 Fax: 262-728-4073 |
Dr. Amar Pattani, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 134 S 4th St, Delavan, WI 53115 Phone: 262-728-9330 |
Dr. Jeffrey J. Winn, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 962 E Wisconsin St, Delavan, WI 53115 Phone: 262-728-9330 Fax: 262-728-0172 |
Dr. John Patrick Smith, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1114 Ann St Ste 1-po # 487, Delavan, WI 53115 Phone: 262-728-8232 Fax: 262-728-8259 |
Maria Teresa Galgano Chadha, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 608 E Walworth Ave, Delavan, WI 53115 Phone: 262-728-6940 Fax: 262-728-4781 |
Dr. Thomas J Schuetz, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 614 E Walworth Ave, Delavan, WI 53115 Phone: 262-728-9117 Fax: 262-728-9118 |
News Archive
Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men
The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease.
Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA
Santarus, Inc. and Pharming Group NV today announced that the U.S. Food and Drug Administration has accepted for filing the Biologics License Application for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.
Global efforts must be coordinated immediately to prevent, control NCDs
In this Scientist opinion piece, Edward Partridge, president of the American Cancer Society and director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, Elizabeth Mayer-Davis, president of health care and education at the American Diabetes Association, and Ralph Sacco, immediate past president of the American Heart Association/American Stroke Association and professor and chairman of neurology at the Miller School of Medicine at the University of Miami, write that while last month's U.N.
NCI launches new drug formulary to help expedite use of agents in clinical studies
The National Cancer Institute today launched a new drug formulary (the "NCI Formulary") that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.
› Verified 8 days ago